g h For over a decade, the world of obesity pharmaceuticals has been stagnant, with most medications that have been studied for use in the management of obesity being rejected or withdrawn due to an unacceptable side effect profile.1 Since the withdrawal of sibutramine in 2010 due to concerns regarding an increased risk of cardiovascular events, the only available medical therapy is orlistat, which provides very modest weight loss, and is poorly tolerated by many patients due to the gastrointestinal side effect profile. On June 27, 2012, lorcaserin was approved by the American FDA for chronic weight management in addition to a reduced calorie diet and exercise, in adults with a BMI ≥30 kg/m2, or a BMI ≥27 kg/m2 with at least one weight related condition such as type 2 diabetes, hypertension, or dyslipidemia. This brings to an end a 13-year era without any approval of newer agents for obesity management, an area where pharmaceutical treatment options are desperately needed. Lorcaserin is an agonist of the 5-hydroxytryptamine (5-HT, or serotonin) receptor 5-HT2C.2 It works selectively on the central 5-HT2C receptors, with a functional selectivity of approximately 15 and 100 times over that for 5-HT2A and 5-HT2B, respectively. The suppression of appetite is predominantly mediated by 5-HT2C as well as 5HT1B receptors. Previously available nonselective serotonergic agents